Immunotherapy using interleukin 13 receptor subunit alpha 2

• US 20020197266A1
• Filed: 02/08/2001
• Published: 12/26/2002
• Est. Priority Date: 02/08/2000
• Status: Abandoned Application

• Current Assignee: Penn State Research Foundation (Pennsylvania State University)
• Original Assignee: Penn State Research Foundation (Pennsylvania State University)
• Inventors: Debinski, Waldemar
• Application Number:
  US09/780,926
• Publication Number:
  US 20020197266A1
• Time in Patent Office: Days
• US Class Current: 424/185.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/001184 Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

Claims

1. A method for stimulating a immune response against IL-13Rα

2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα

2, the method comprising the steps of;

(a) formulating an anti-cancer vaccine outside of the subject, the vaccine comprising an agent that can stimulate an immune response against IL-13Rα

2 when administered to an animal; and

(b) administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα

2 in the subject.

2. The method of claim 1, wherein the agent that can stimulate an immune response against IL-13Rox2 comprises a peptide comprising at least seven contiguous amino acids of SEQ ID NO:

1.

3. The method of claim 1, wherein the agent that can stimulate an immune response against IL-13R.α

2 is a protein comprising the amino acid sequence of SEQ ID NO;

1.

4. The method claim 1, wherein the vaccine further comprises an adjuvant.

5. The method of claim 4, wherein the adjuvant comprises a substance selected from the group consisting of:

an aluminum salt;

an oil-in-water emulsion;

a composition comprising saponin;

a composition comprising a bacterial protein; and

a cytokine.

6. The method of claim 4, wherein step (b) of administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα

2 in the subject comprises administering the vaccine in at least a first dose and a second dose, wherein said first dose is administered to the subject at least 24 hours before said second dose is administered to the subject.

7. The method of claim 1, wherein the agent that can stimulate an immune response against IL-13Rα

2 comprises a nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

8. The method of claim 7, wherein the nucleic acid is a naked DNA.

9. The method of claim 7, wherein the nucleic acid is incorporated into an expression vector.

10. The method of claim 1, wherein the agent that can stimulate an immune response against IL-13Rα

2 comprises a cell expressing a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

11. The method of claim 10, wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:

1 is a protein comprising the amino acid sequence of SEQ ID NO;

1.

12. The method of claim 1, wherein the agent that can stimulate an immune response against IL-13Rα

2 comprises a cell into which has been introduced a purified nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

13. The method of claim 1, further comprising the step of providing a subject having or at risk for developing a cancer having cells expressing IL-13Rα

2.

14. The method of claim 13, wherein the cells expressing IL-13Rβ

α

2 are glioma cells.

15. The method of claim 13, wherein the subject is a human being.

17. The composition of claim 16, wherein the agent that can stimulate an immune response against IL-13Rα

2 when administered to an animal comprises a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

18. The composition of claim 17, wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:

1 is a protein comprising the amino acid sequence of SEQ ID NO;

1.

19. The composition of claim 17, wherein the composition further comprises an adjuvant.

20. The composition of claim 19, wherein the adjuvant comprises a substance selected from the group consisting of:

an aluminum salt;

an oil-in-water emulsion;

a composition comprising saponin;

a composition comprising a bacterial protein; and

a cytokine.

21. The composition of claim 20, wherein the agent that can stimulate an immune response against IL-13Rα

2 when administered to an animal comprises a nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

22. The composition of claim 21, wherein the nucleic acid is a naked DNA.

23. The composition of claim 21, wherein the nucleic acid is incorporated into an expression vector.

24. The composition of claim 20, wherein the agent that can stimulate an immune response against IL-13Rα

2 comprises a cell expressing a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

25. The method of claim 24, wherein the peptide comprising at least seven contiguous amino acids of SEQ ID NO:

1 is a protein comprising the amino acid sequence of SEQ ID NO;

1.

26. The composition of claim 25, wherein the agent that can stimulate an immune response against IL-13Rα

2 comprises a cell into which has been introduced a purified nucleic acid that encodes a peptide comprising at least seven contiguous amino acids of SEQ ID NO;

1.

28. The method of claim 27, wherein the antibody is a monoclonal antibody.

29. The method of claim 27, wherein the antibody is a polyclonal antibody.

16. A composition for stimulating an immune response against IL-13Rα

2 when administered to an animal, the composition comprising;

(a) an isolated agent that can stimulate an immune response against IL-13Rα

2 when administered to an animal; and

(b) a pharmaceutically acceptable carrier.

27. A method for directing an antibody to cells expressing IL-13RU,2 in a subject, the method comprising the steps of:

(a) formulating a pharmaceutical composition outside of a subject, the pharmaceutical composition comprising an antibody that specifically binds IL-13Rα

2 and a pharmaceutically acceptable carrier; and

(b) administering the pharmaceutical composition to the subject in an amount sufficient to allow the antibody to specifically bind to the cells expressing IL-13Rα

2 in the subject.

30. A pharmaceutical composition comprising an antibody that specifically binds IL-13Rα

2 and a pharmaceutically acceptable carrier.

31. The pharmaceutical composition of claim 30, wherein the antibody is a monoclonal antibody.

32. The pharmaceutical composition of claim 30, wherein the antibody is a polyclonal antibody.